First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence
1998

First-line chemotherapy for advanced ovarian cancer: paclitaxel, cisplatin and the evidence

Sample size: 410 publication Evidence: moderate

Author Information

Author(s): J Sandercock, MKB Parmar, V Torri

Primary Institution: MRC Cancer Trials Office

Conclusion

Cisplatin combined with paclitaxel is more effective than cisplatin combined with cyclophosphamide, although one trial suggests single-agent cisplatin may be equally effective.

Supporting Evidence

  • Cisplatin combined with paclitaxel shows improved overall survival compared to cyclophosphamide.
  • One trial suggests that a higher dose of single-agent cisplatin may be as effective as the combination treatment.
  • Statistical tests indicate significant differences in survival outcomes between treatment groups.

Takeaway

Doctors are trying to find the best way to treat advanced ovarian cancer, and they think a mix of two medicines, paclitaxel and cisplatin, works better than one medicine alone.

Methodology

Four randomized trials were compared, focusing on the effectiveness of paclitaxel and cisplatin versus other treatments.

Potential Biases

Potential false-positive and false-negative results in trials could affect the conclusions.

Limitations

The results of one trial were not available, and there was considerable statistical and clinical heterogeneity among the trials.

Participant Demographics

Patients with advanced ovarian cancer, specifically FIGO stage IIIB or IV.

Statistical Information

P-Value

0.00041

Confidence Interval

(0.53-0.83)

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication